Time: 2024-07-30
Pfizer recently reported second - quarter earnings that surpassed expectations and increased its full - year outlook , attributing the success to its cost - cutting initiatives , strong sales of its Covid antiviral pill Paxlovid , and robust non - Covid product sales . The company now projects adjusted earnings of .45 to .65 per share for the fiscal year , up from .15 to .35 per share previously . Additionally , Pfizer raised its revenue forecast to 9.5 billion to 2.5 billion , including an estimated billion from its Covid vaccine and .5 billion from Paxlovid.
This positive outlook reflects Pfizer 's strong performance in the first half of the year and its confidence in the underlying strength of its business . The pharmaceutical giant is focused on stabilizing its operations following a decrease in demand for its Covid products . To combat this , Pfizer initiated a cost - cutting program with a goal of saving billion by 2024 and announced plans to reduce costs by .5 billion by 2027 . Furthermore , Pfizer is investing in cancer treatment following its acquisition of Seagen for 3 billion last year.
For the second quarter , Pfizer reported adjusted earnings per share of 60 cents , exceeding Wall Street 's expectations of 46 cents . The company 's revenue of 3.28 billion also surpassed analysts ' estimates of 2.96 billion . Notably , Pfizer 's net income for the quarter was 1 million , or 1 cent per share , compared to .33 billion , or 41 cents per share , a year ago . Sales of Paxlovid increased by 76 % to 51 million , while revenue from the Covid vaccine declined by 87 % to 95 million due to lower deliveries and demand.
Despite facing a revenue decline from Covid products , Pfizer raised its annual profit forecast , supported by strong sales of its heart disease drug and new cancer treatments from the Seagen acquisition . The company now expects annual revenue of .5 billion from Paxlovid , up from billion . Pfizer 's strategic focus on cancer treatments and other key products has helped offset losses from the Covid market . The acquisition of Seagen has been instrumental in diversifying Pfizer 's portfolio and driving revenue growth.
In conclusion , Pfizer 's impressive second - quarter performance and increased full - year outlook demonstrate the company 's resilience in the face of changing market dynamics . By leveraging its cost - cutting initiatives , strong product sales , and strategic acquisitions , Pfizer continues to position itself for long - term success in the pharmaceutical industry.
Business
